Gain Therapeutics GANX Stock
Gain Therapeutics Price Chart
Gain Therapeutics GANX Financial and Trading Overview
| Gain Therapeutics stock price | 1.8 USD |
| Previous Close | 1.88 USD |
| Open | 1.88 USD |
| Bid | 1.39 USD x 200 |
| Ask | 2.39 USD x 200 |
| Day's Range | 1.84 - 1.95 USD |
| 52 Week Range | 1.41 - 4.34 USD |
| Volume | 790.61K USD |
| Avg. Volume | 592.57K USD |
| Market Cap | 78.91M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.2 USD |
GANX Valuation Measures
| Enterprise Value | 63.04M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.0833333 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.6060605 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.205 |
Trading Information
Gain Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 3.35% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 4.34 USD |
| 52 Week Low | 1.41 USD |
| 50-Day Moving Average | 1.84 USD |
| 200-Day Moving Average | 2.2 USD |
GANX Share Statistics
| Avg. Volume (3 month) | 592.57K USD |
| Avg. Daily Volume (10-Days) | 595.48K USD |
| Shares Outstanding | 42.65M |
| Float | 41.65M |
| Short Ratio | 5.13 |
| % Held by Insiders | 2.28% |
| % Held by Institutions | 19.24% |
| Shares Short | 3.2M |
| Short % of Float | 7.67% |
| Short % of Shares Outstanding | 7.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -81.16% |
| Return on Equity (ttm) | -214.68% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -10073427 USD |
| EBITDA | -19669370 USD |
| Net Income Avi to Common (ttm) | -21239772 USD |
| Diluted EPS (ttm) | -0.58 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 16.54M USD |
| Total Cash Per Share (mrq) | 0.39 USD |
| Total Debt (mrq) | 672.3K USD |
| Total Debt/Equity (mrq) | 4.8 USD |
| Current Ratio (mrq) | 4.688 |
| Book Value Per Share (mrq) | 0.33 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19371432 USD |
| Levered Free Cash Flow (ttm) | -11122230 USD |
Profile of Gain Therapeutics
| Country | United States |
| State | MD |
| City | Bethesda |
| Address | 4800 Montgomery Lane |
| ZIP | 20814 |
| Phone | 301 500 1556 |
| Website | https://gaintherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 20 |
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Q&A For Gain Therapeutics Stock
What is a current GANX stock price?
Gain Therapeutics GANX stock price today per share is 1.8 USD.
How to purchase Gain Therapeutics stock?
You can buy GANX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Gain Therapeutics?
The stock symbol or ticker of Gain Therapeutics is GANX.
Which industry does the Gain Therapeutics company belong to?
The Gain Therapeutics industry is Biotechnology.
How many shares does Gain Therapeutics have in circulation?
The max supply of Gain Therapeutics shares is 42.65M.
What is Gain Therapeutics Price to Earnings Ratio (PE Ratio)?
Gain Therapeutics PE Ratio is now.
What was Gain Therapeutics earnings per share over the trailing 12 months (TTM)?
Gain Therapeutics EPS is -0.58 USD over the trailing 12 months.
Which sector does the Gain Therapeutics company belong to?
The Gain Therapeutics sector is Healthcare.
Gain Therapeutics GANX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25620.17 USD — |
-2.09
|
11.94B USD — | 25513.26 USD — | 25882.57 USD — | — - | 11.94B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2309.81 USD — |
-1.1
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.99 USD — |
+0.78
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}